Liver disease Novo's Wegovy in August became the first GLP-1 therapy approved in the U.S. to treat adults with metabolic ...

This episode of Pharma Pulse covers Novo Nordisk’s FDA win for Wegovy in MASH-related liver fibrosis, new research on a ...

Shares of Novo Nordisk NVO climbed nearly 4% on Monday after its famous obesity drug, Wegovy, received accelerated approval from the U.S. Food and Drug Administration (FDA) to treat a serious liver ...

Andersen has a fair value estimate of $71 for Novo stock. Closing around $52.41 on Aug. 15 (near its lowest level since ...

At this year's conference, Landmark Science spotlights real-world evidence's power to drive GLP-1 and Wegovy insights in Medicare and shape regulatory decision-making.

FDA has approved Novo Nordisk's Wegovy, one-weekly 2.4 mg semaglutide injection for treating metabolic-associated ...

Novo Nordisk stock rallies as the Danish pharma giant makes two big announcements. TD Cowen analysts recommend buying NVO ...

The string of negative updates from Novo Nordisk and positive news flow from the main competitor Eli Lilly has finally ended ...

Novo Nordisk reduces Ozempic's price to $499/month for self-paying patients, enhancing access to essential diabetes treatment ...

The FDA has approved Novo Nordisk’s Wegovy to treat metabolic associated steatohepatitis, or MASH, in adults who have excessive scar tissue in the liver. MASH is a serious liver condition linked to ...

The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...

Shares in Danish pharma company Novo Nordisk jumped after it halved the out-of-pocket price of Ozempic in the US and gained ...